Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Health Care Among Early Leaders In The S&P 500


Published on

  • Be the first to comment

  • Be the first to like this

Health Care Among Early Leaders In The S&P 500

  1. 1. Health Care Among Early Leaders In The S&P 500[US Market News] We search to locate the breaking news storiesfrom worldwide. The post below is sourced from the latest US Market News.Read on to learn more:NEW YORK (AP) – Health care stocks have started off the year on a tear.The industry group that includes health care providers, drugmakers and biotechnologycompanies has advanced 7.3 percent this year, making it the second-best in the Standard andPoor’s 500 index, trailing only energy companies. Even drugmakers, traditionally considered asafe-haven play, are outperforming the market.The rally has solid foundations, but not all companies will benefit equally from the influx of cash.Also, the wide range of stocks in the sector offer investors vastly differing risk and returndynamics.U.S. health care spending is projected to climb at a faster pace than economic growth in comingyears as the population ages and President Barack Obama‘s Affordable Care Act gives millionsof Americans greater access to care.The Centers for Medicare and Medicaid Services projects that total health care spending willrise 70 percent over last year’s estimated level of $2.8 trillion to $4.8 trillion by 2021. That’salmost 20 percent of U.S. gross domestic product.“There’s just a lot more money flowing into health care and we’re seeing the markets reactaccordingly,” says Derek Taner, a portfolio manager at Invesco.President Obama‘s re-election in November gave the sector a boost by removing theuncertainty surrounding the implementation of the Affordable Care Act. Republican candidateMitt Romney had said that he would overturn the act if elected.The biggest beneficiaries of the act will likely be hospital companies, which have the potential toincrease their earnings significantly, says Taner, who manages Invesco‘s Global Health Carefund.So-called managed-care companies should also benefit from the increase in spending, thoughthey also face higher taxes and restrictions on how they can price their coverage, so the law willbe challenging to them too.HCA Holdings Inc., a bellwether for the hospital industry, has gained 25 percent so far this year.Tenet Healthcare Corp., a Dallas-based operator of acute care hospitals, has advanced 20percent. 1/4
  2. 2. Drugmakers, often regarded as defensive growth companies by analysts, are also emergingfrom the doldrums after lagging the broader index for much of the last decade.Pfizer Inc., the world’s biggest drugmaker by revenue, has returned 31 percent over the last 10years, compared with 113 percent for the S&P 500.The big pharmaceutical companies were shunned by investors as they faced challenges fromrising research costs and the economic slump in Europe, which prompted governments to try torein in health care spending.Drug companies were also hurt by what the industry dubbed the “patent cliff,” as anunprecedented number of patents expired on drugs worth billions of dollars in sales. Theexpiration of patents allows cheaper generic versions of drugs to replace blockbuster products.That hurts sales.Pfizer lost exclusivity for its cholesterol-fighting drug Lipitor in the U.S. in November 2011. In itsmost recent earnings report, Pfizer said that U.S. revenues from the drug plunged 87 percent inthe third quarter of 2012 to $192 million. The company will release its fourth-quarter earningsTuesday.The worst of the impact of patent expiration may now be over for the drugmakers, and themarket has already factored it into stock prices, says Mark Bussard, a health care analyst atfund manager T. Rowe Price.“The ‘patent cliff’ for most of the companies has now come and gone,” says Bussard, who is aphysician by training. “Some of the largest losses to generic competition are in the rear-viewmirror now.”Approvals for first-of-a-kind drugs have also been climbing as drugmakers continue to pursuean emerging business model focused on treatments for rare and hard-to-treat diseases.The Food and Drug Administration approved 39 new drugs last year, up from 30 the year beforeand the highest annual tally since 1997, when the agency also approved 39 drugs.In addition to being relatively low-risk investments, due to the steady demand for drugs, BigPharma also pays big dividends.The largest drug companies in the S&P 500 have higher dividend yields than the broader index,which yields 2.1 percent. Pfizer currently has a 3.6 percent yield and Merck & Co. yields 4percent.Biotechnology companies are possibly the most exciting companies in the sector and are alsoadvancing.Investing in this sector can be challenging, though, as the vast majority of drugs beingdeveloped don’t work out. 2/4
  3. 3. “It’s probably unwise … to try to pick the individual winner,” says Sam Isaly, the manager ofEaton Vance’s Worldwide Health Sciences Fund. “It depends on whether you’re a lotto playeror not.”While the Affordable Care Act ensures that money will flow into the industry in the near term,that spending can’t keep rising exponentially. At some point, the focus will turn to the cost ofthe reforms, particularly if the initial spending estimates are exceeded, causing reneweduncertainty for the industry.“That’s a longer-term concern that is going to come into play at some point,” says Invesco’sTaner. “Right now we’re in the honeymoon period. People aren’t thinking about that.”And if history is a guide, the cost estimates will likely prove too low.Upon passing the Medicare bill in 1965, the House Ways and Means Committee estimated totalprogram expenditures would amount to $1.3 billion in 1967. That estimate proved to be “wildlyoptimistic,” with the actual cost coming in at $4.6 billion, according to research by Citigrouphealth care analysts.To counter the rising costs, governments and employers will increasingly try to shift more of thecost to individual consumers, transforming the industry from an “employer-driven insurancemarket” to an “employee-driven consumer market,” says Eddie Yoon of Fidelity.“The companies that are the most innovative in helping drive costs down are going to be thegrowth companies of tomorrow,” says Yoon, who manages the investment firm’s Select HealthCare Portfolio.___AP Business Writers Matthew Perrone and Linda Johnson contributed.Check out the original source here.We hope that you found the above write-up was of value. Please feel free to share this post.Keeping up with the Market News from around the globe is important for investors and tradersalike. Whether it is political, economic or social changes which could influence your investmentsin the short, medium or long term, it’s great to be in the understand.We aspire to bring you the most recent news as it breaks, so you are ahead of the majority ofinvestors and traders . 3/4
  4. 4. 4/4Powered by TCPDF (